摘要
背景:HE4可能是妇科癌症复发的有价值的早期指标。 许多研究表明血清HE4的高表达水平与卵巢和子宫内膜癌复发相关。 高HE4水平可能是预测这些癌症预后不良的独立因素。 目的:本研究回顾了血清HE4水平与卵巢癌和子宫内膜癌复发之间的关系。 结论:HE4通过促进癌细胞从G1期跳至S期,维持细胞活力,促进细胞增殖,抑制细胞凋亡,增加药物治疗抗性,显示恶性行为。 需要进一步的研究来验证血清HE4水平升高与卵巢癌和子宫内膜癌的复发相关。
关键词: HE4,妇科癌症,卵巢癌,子宫内膜癌,癌症复发,预后。
图形摘要
Current Drug Targets
Title:Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
Volume: 18 Issue: 10
关键词: HE4,妇科癌症,卵巢癌,子宫内膜癌,癌症复发,预后。
摘要: Background: HE4 may be a valuable early indicator of the recurrence of gynecologic cancers. Numerous studies have shown that high expression levels of serum HE4 correlate with ovarian and endometrial cancer recurrence. High HE4 levels may be an independent factor to predict these cancers’ poor prognosis.
Objective: This literature review investigates the relationship between serum HE4 levels and the recurrence of ovarian and endometrial cancer. Conclusion: HE4 displays malignant behavior by promoting cancer cells to skip from G1 phase to S phase, maintaining cell viability, encouraging cell proliferation, inhibiting cell apoptosis, and increasing resistance to drug treatments. Further studies are required to verify that elevated serum HE4 levels correlate with the recurrence of ovarian and endometrial cancer.Export Options
About this article
Cite this article as:
Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170404154929
DOI https://dx.doi.org/10.2174/1389450118666170404154929 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecule of the Month
Current Topics in Medicinal Chemistry The Clinical Perspective on Value of 3D, Thin Slice T2-Weighted Images in 3T Pelvic MRI for Tumors
Current Medical Imaging Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy
Clinical Cancer Drugs The Importance of TLR3 Expression and Hormonal Regulation of TLR3- Induced Immune Responses in the Human Endometrium
Current Immunology Reviews (Discontinued) Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Functions of S100 Proteins
Current Molecular Medicine The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry The Role of Obesity in the Development of Polycystic Ovary Syndrome
Current Pharmaceutical Design Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Anti-Cancer Potential of Some Commonly Used Drugs
Current Pharmaceutical Design Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen
Current Signal Transduction Therapy Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets FOXO1: A Potential Target for Human Diseases
Current Drug Targets Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design